Meola Mario, Petrucci Ilaria, Barsotti Giuliano
Department of Internal Medicine, S Anna School of Advanced Studies, Nephrology and Dialysis Unit, University of Pisa, Italy.
Nephrol Dial Transplant. 2009 Mar;24(3):982-9. doi: 10.1093/ndt/gfn654. Epub 2009 Jan 30.
The effect of cinacalcet on the structural pattern of hyperplastic parathyroid glands was evaluated, using high-resolution colour Doppler (CD) sonography, in haemodialysis patients with severe, inadequately controlled, secondary hyperparathyroidism (sHPT).
Nine patients (6 males, 3 females; mean age +/- SD, 55.5 +/- 12.6 years) received cinacalcet, with adaptation of existing concomitant therapies. Biochemical parameters and the morphology and vascular pattern of hyperplastic parathyroid glands were measured at baseline and every 6 months thereafter, for a follow-up period of 24-30 months.
At baseline, 28 hyperplastic glands were identified. Cinacalcet led to a reduction in glandular volume during the course of the study: 68% in glands with a baseline volume <500 mm(3) and 54% in glands with a baseline volume >or=500 mm(3). The mean volume +/- SD of glands <500 mm(3) changed significantly from the baseline (233 +/- 115 mm(3)) to the end of follow-up (102 +/- 132 mm(3), P = 0.007). Levels of mean serum phosphorus, calcium and calcium-phosphorus product decreased, but not significantly, whereas there were significant decreases in mean parathyroid hormone +/- SD levels (1196 +/- 381 pg/ml versus 256 +/- 160 pg/ml; P < 0.0001) and alkaline phosphatase +/- SD levels (428 +/- 294 versus 223 +/- 88 IU/l; P = 0.04), accompanied by an improvement in a subjective clinical score.
Cinacalcet, in combination with conventional treatments, led to an improvement in biochemical and clinical parameters of sHPT and reduced glandular volume in patients with severe sHPT. Volume reduction was more evident in smaller glands. Longer term, larger, randomized clinical trials are needed to confirm these preliminary findings and to further define a more systematic approach in the treatment of sHPT.
采用高分辨率彩色多普勒(CD)超声检查,评估西那卡塞对严重、控制不佳的继发性甲状旁腺功能亢进症(sHPT)血液透析患者增生性甲状旁腺腺体结构模式的影响。
9例患者(6例男性,3例女性;平均年龄±标准差,55.5±12.6岁)接受西那卡塞治疗,并调整现有的联合治疗方案。在基线时以及此后每6个月测量生化参数以及增生性甲状旁腺腺体的形态和血管模式,随访期为24 - 30个月。
基线时,共识别出28个增生性腺体。在研究过程中,西那卡塞使腺体体积减小:基线体积<500 mm³的腺体减小68%,基线体积≥500 mm³的腺体减小54%。基线体积<500 mm³的腺体平均体积±标准差从基线时的(233±115 mm³)显著变化至随访结束时的(102±132 mm³,P = 0.007)。平均血清磷、钙和钙磷乘积水平有所下降,但无显著差异,而平均甲状旁腺激素±标准差水平(1196±381 pg/ml对256±160 pg/ml;P < 0.0001)和碱性磷酸酶±标准差水平(428±294对223±88 IU/l;P = 0.04)显著下降,同时主观临床评分有所改善。
西那卡塞与传统治疗方法联合使用,可改善sHPT的生化和临床参数,并减小严重sHPT患者的腺体体积。体积减小在较小的腺体中更为明显。需要进行更长期、更大规模的随机临床试验来证实这些初步发现,并进一步确定治疗sHPT更系统的方法。